Cadalimab (adalimumab biosimilar) / Cadila - LARVOL DELTA

The Evolving Spectrum of TNF Inhibitors in the Management of Psoriatic Disease - Episode 9 : Case Presentation: 45-Year-Old Caucasian Male Diagnosed With Psoriasis (DermatologyTimes) - "Mark G. Lebwohl, MD: Let me close with the case of a 45-year-old White man diagnosed with psoriasis who presents with increasing joint pain and stiffness, generally in the morning. He was diagnosed with moderate to severe psoriasis 8 years ago. During that time, he has tried several biologics, including adalimumab, ustekinumab, secukinumab, and ixekizumab. He noted that these were all successful at first but less efficacious over time. Upon examination, erythematous-scaling plaques cover 12% to 15% of the body surface area, primarily on the upper bilateral legs. Additionally, the patient noted that he has never been evaluated by a rheumatologist and has no history of bowel issues. His past medical history is noteworthy for hypertension managed with lisinopril, diabetes managed by metformin, hypercholesterolemia managed with atorvastatin, and obesity. His BMI is 32.1, and he has both psoriasis and psoriatic arthritis."

Video • Psoriasis

3-Drug Regimen With 2 Biologics Deployed in High-Risk Crohn’s Trial (Gastroendonews) - '"Although biologics have revolutionized treatment of Crohn's disease, an efficacy plateau has been reached,' according to Dr. Colombel. 'Combining biologic therapies, such as vedolizumab and adalimumab, may be effective in overcoming this plateau'....'Although biologics have revolutionized treatment of Crohn's disease, an efficacy plateau has been reached,' according to Dr. Colombel. 'Combining biologic therapies, such as vedolizumab and adalimumab, may be effective in overcoming this plateau.'"

Media quote

Biosimilars for Chronic Inflammation Management - Episode 10: How to Switch Patients to Biosimilars (DermatologyTimes) - "Joel M. Gelfand, MD, MSCE, FAAD: Yes, but when person has done well on the originator product then lost response over time, do you think they have a chance of recapturing [response] when they go on a biosimilar?....In my own practice, one of the big challenges with the treatment of psoriasis is that some patients tend to cycle through therapies. They do well for a period, then lose response. Then they do well, then lose response again. I worry about those individuals because they eventually start running out of options."

Video • Psoriasis

Picks From the Crohn’s & Colitis Congress, Part 1 (Gastroendonews) - "We now have more medicines in our inflammatory bowel disease clinical armamentarium than ever before. This is great news for patients, but a question that often comes up for clinicians is, 'What is the best order to administer these drugs?'...Vedolizumab followed by adalimumab led to the lowest rates of adverse IBD-related outcomes, including hospitalizations, surgeries and colorectal cancer."

Media quote

Different Forms of Adalimumab Safe, Effective in RA Patients (HCPLive) - "Roy Fleischmann...evaluated the efficacy, safety, and immunogenicity of ADL-PF (an adalimumab biosimilar approved for the treatment of several inflammatory and autoimmune indications) and ADL-EU in patients with moderate to severe rheumatoid arthritis on longer-term treatment....In the multinational, randomized, double-blind, parallel-group study, Fleischmann and the investigators compared ADL-PF and ADL-EU in essentially biologic-naïve patients with rheumatoid arthritis despite methotrexate."

Media quote